Related Experiment Video
Updated: Sep 4, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Influence of halloysite nanotubes on the efficiency of Asparaginase against mice Ehrlich solid carcinoma
B M M Baharoon1, A M Shaik1,2, Salim M El-Hamidy1,2
1Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Abstract:
Herein, the impact of the halloysite nanotubes to suppress the side effects of Asparaginase (ANase) cellular proliferation was investigated. Methods: A total of 100 adult male mice was employed. These mice were divided into four equal groups; Group 1 (control), Group 2 (ESC group) of a single dose of 0.15 ml Ehrlich cells (2 × 106) intraperitoneal infusion(IP), Group 3 (ESC + ANase group) received six doses equal treatments of Intratumoral (IT) 0.07 ml Aspragnase (7 mg/kg) over two weeks. For two weeks, Group 4 (ESC + ASNase + HNTs) received an IT administration of 0.07 ml Asparaginase stocked on Halloysite nanotubes (HNTs) (30 mg/kg) three times per week. A blood specimen was collected, and the liver was removed to be investigated histologically. Results: TEM measurements for the Halloysite nanoclay showed their tubular cylindrical shape with a mean diameter of 50 nm and an average length of 1 μm, whereas The X-ray diffraction pattern of the Halloysite nanoclay showed their characteristic peaks. ESC increases the serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin than control and other groups, even as albumin and total protein were decreasing. After using Halloysite Nanotube, the rates of these variables were enhanced up to 75%. The hepatocytes histological studies showed protection against Ehrlich Solid carcinoma-induced degenerative, necrotic, and inflammatory changes up to 70%. In conclusion, halloysite nanotubes have demonstrated effective removal of Ehrlich solid carcinoma in mice using an ASNase delivery system. It promoted the ASNase to inhibit the adverse effect of ANase's on the liver and remove the tumour cells.
Insights
Halloysite nanotubes deliver Asparaginase effectively, suppressing Ehrlich solid carcinoma in mice. This nanotechnology also mitigates Asparaginase
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Ehrlich solid carcinoma (ESC) poses a significant challenge in cancer research.
- Asparaginase (ANase) is a chemotherapeutic agent with potential side effects.
- Halloysite nanotubes (HNTs) offer a promising platform for drug delivery.
Purpose of the Study:
- To investigate the efficacy of halloysite nanotubes (HNTs) in delivering Asparaginase (ASNase).
- To evaluate the impact of HNTs-ASNase on suppressing Ehrlich solid carcinoma (ESC) in mice.
- To assess the protective effects of HNTs against ASNase-induced liver toxicity.
Main Methods:
- Characterization of halloysite nanotubes using TEM and X-ray diffraction.
- Administration of Ehrlich cells, Asparaginase, and HNTs-ASNase to mouse models.
- Analysis of liver function markers (AST, ALT, ALP, bilirubin, albumin, total protein) in serum.
- Histological examination of liver tissues to assess cellular damage.
Main Results:
- Halloysite nanotubes exhibited characteristic tubular morphology.
- ESC induction significantly altered liver function markers, which were improved by HNTs-ASNase treatment up to 75%.
- Histological analysis revealed up to 70% protection of hepatocytes against ESC-induced damage.
Conclusions:
- Halloysite nanotubes serve as an effective delivery system for Asparaginase in cancer therapy.
- HNTs-ASNase demonstrated significant tumor suppression and hepatoprotective effects.
- This nanotechnology approach holds potential for improving cancer treatment outcomes.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015